Our presenters were:
Desmoid tumors: the nonmalignant malignancy.
Lor Randall, MD, FACS
Director of Sarcoma Services
Huntsman Cancer Institute, University of Utah
Magnetic Resonance Guided Focused Ultrasound Treatment for desmoid tumors.
Raffi S. Avedian, MD
Assistant Professor of Orthopaedic Surgery
Stanford University
Tegavivint (BC-2059), an emerging potential treatment for desmoid tumors.
Jon Northrup
CEO & Co-Founder
Iterion Therapeutics (formerly Beta Cat Pharmaceuticals, Inc.)
Yating Wong
Mother of pediatric desmoid tumor patient
Nirogacestat (a gamma secretase inhibitor) in desmoid tumors.
Victor Villalobos, MD, PhD
Assistant Professor, Director of Sarcoma and T3 (Target-based Therapeutics Team)
University of Colorado - Denver
Phase 3 Nirogacestat clinical study update.
Mary Smith, PhD
Vice President of Clinical Research & Development
SpringWorks Therapeutics
The Natural History of Desmoid Tumors: What we are learning from the DTRF Patient Registry and Natural History Study.
Kelly Mercier, PhD
Adjunct associate
Duke University
DeAnn Sorensen
Co-administrator
The Desmoidian
